psilocybin sod
Phase 2Small molecule
psilocybin sod is one of 12 small molecule programs targeting Major Depression. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Major Depression
#DrugCompanyPhaseTrials
1Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Psilocybin
COMPASS PathwaysPhase 3
Actemra
CCelltrion
Phase 2
psilocybin sod
SSection for Affective Disorders; Northern Stockholm Psychiatry
Phase 2
D-Cycloserine
MMassachusetts General Hospital
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
NRX-101
NNeuroRx, Inc.
Phase 1
SP-624
SSirtsei Pharmaceuticals, Inc.
Phase 1
Ropinirole CR
GSKPreclinical
Choline Alphoscerate
SSamsung Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depression1 trial
Cancer Related Major Depression Treated With a Single Dose of Psilocybin
Recruiting·SSection for Affective Disorders; Northern Stockholm Psychiatry·Phase 2·NCT06319378·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for psilocybin sod. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details